Neutralizing Antibodies for Botulinum Neurotoxin Serotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for botulism lack effective small molecule drugs and highly potent recombinant monoclonal antibodies that can neutralize multiple botulinum neurotoxin serotypes, which are needed due to the toxin's high lethality and potential as a bioterrorism agent, and are complicated by the variability of the toxin's gene and protein sequences across serotypes.
Innovation Solution
Development of neutralizing antibodies that bind multiple subtypes of botulinum neurotoxin with high affinity, including combinations of antibodies targeting different epitopes, to achieve potent neutralization across various serotypes such as BoNT/A, BoNT/B, and BoNT/E, using specific VH and VL complementarity determining regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule drugs or existing antitoxins are used, then treatment is available, but the potency is insufficient and cross-reactivity across multiple serotypes is limited
Solution Approach 1:
The patent combines multiple monoclonal antibodies with different specificities (e.g., M393 targeting BoNT/A, M10 targeting BoNT/B, M6 targeting BoNT/E) into a single therapeutic composition. This merging of multiple antibody agents enables simultaneous neutralization of multiple botulinum serotypes while maintaining high potency for each individual serotype, resolving the contradiction between specialized potency and broad cross-reactivity.
Solution Approach 2:
The patent creates a universal antitoxin formulation that can neutralize multiple serotypes (A, B, E, and potentially others) through a single multi-antibody composition. Each antibody in the mixture is engineered to recognize conserved epitopes or dominant variants within specific serotypes, providing multi-functional coverage that addresses both the need for high potency and broad adaptability.
2Reliability
If highly potent monoclonal antibodies are developed for single serotypes, then neutralization potency increases, but the ability to treat multiple serotypes decreases
Solution Approach 1:
The patent segments the neutralization function across multiple specialized monoclonal antibodies, each optimized for a specific serotype or subtype. Rather than creating a single antibody that attempts to recognize all serotypes (which would compromise potency), the therapy divides the neutralization task into specialized components that collectively provide both high potency and broad coverage when used in combination.
3Quantity of substance
If existing equine or human immune globulin is used, then treatment is available, but the supply is limited and potency varies
Solution Approach 1:
The patent employs recombinant DNA technology to enable mammalian cells (such as CHO or HEK 293 cells) to produce the monoclonal antibodies autonomously. This self-service production system allows for scalable, consistent, and unlimited supply of high-potency antibodies without dependence on animal donors or human plasma collection, resolving both the supply limitation and potency variability issues of traditional antitoxins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these antibodies significantly increases the potency of botulinum neurotoxin neutralization, potentially reaching LD50 levels of 10,000 to 25,000 mouse units per milligram, providing a more effective treatment for botulism and addressing the variability across serotypes.
Implementation Method 1
neutralizing antibodies that bind two or more subtypes of the particular neurotoxin serotype with high affinity
Data Source
AI summary
This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.